|
|
Article: VaxGen Phase I/II Study of Attenuated Smallpox Vaccine Candidate Completes Enrollment.
- Article from:
- PR Newswire
- Article date:
- July 11, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BRISBANE, Calif., July 11 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN.PK) announced today that it has completed enrollment of 153 volunteers in a Phase I/II clinical trial designed to evaluate the safety of and immune response to its attenuated smallpox vaccine candidate, LC16m8. LC16m8 has been licensed in Japan and forms the basis of that country's strategic national stockpile of smallpox vaccine. Data from this trial will be presented at a scientific meeting later this year.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )
Medical centers participating in the study include Saint Louis University Health Sciences Center, ...